Press Room

  • Press Release
  • Industry News
  • Publication & Congress
Publication and Congress - June 10, 2024

Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition

Current Research in Pharmacology and Drug Discovery
Industry News - May 08, 2024

Investigational Anticoagulant May be Cost Effective

Managed Healthcare Executive
Publication and Congress - April 11, 2024

Targeting factor XI and factor XIa to prevent thrombosis

Blood
Industry News - March 21, 2024

New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding

Wall Street Journal
Industry News - November 15, 2023

InnovationRx: A New Blood Thinner On The Horizon

Forbes
Industry News - November 14, 2023

Anthos blood thinner bests Xarelto on safety in mid-stage study

Bio Pharma Dive
Industry News - November 12, 2023

New anti-clotting medication reduces bleeding among people with atrial fibrillation

American Heart Association
Publication and Congress - April 12, 2023

News at XI: moving beyond factor Xa inhibitors

Journal of Thrombosis and Haemostasis
Industry News - March 31, 2022

NPR Tech Nation Radio with CMO Dan Bloomfield, MD, FACC, FAHA

NPR Tech Nation
Industry News - August 04, 2021

Bleeding Edge: Anthos Pursues a Monthly Anticoagulant

Genetic Engineering and Biotechnology News
Publication and Congress - July 29, 2021

Abelacimab for Prevention of Venous Thromboembolism

The New England Journal of Medicine
Publication and Congress - July 22, 2021

Factor XI Inhibition to Uncouple Thrombosis From Hemostasis

Journal of the American College of Cardiology
Industry News - September 23, 2019

FierceBiotech’s 2019 Fierce 15

Fierce Biotech
Industry News - February 27, 2019

Blackstone, Novartis found cardiovascular startup with $250M

Fierce Biotech